AxoGen, Inc. (NASDAQ:AXGN) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET
Company Participants
Adanna Alexander - Investor Relations Consultant
Karen Zaderej - Chairman, Chief Executive Officer and President
Pete Mariani - Executive Vice President and Chief Financial Officer
Conference Call Participants
Michael Sarcone - Jefferies
Dave Turkaly - JMP Securities
Ross Osborn - Cantor Fitzgerald
Caitlin Cronin - Canaccord Genuity
Chris Pasquale - Nephron Research
Operator
Greetings. Welcome to the AxoGen, Inc. Reports Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
At this time, I would like to hand the call over to, Adanna Alexander, Investor Relations Consultant. Thank you. You may begin.
Adanna Alexander
Thank you, Darryl. Good evening, everyone.
Joining me on today’s call is Karen Zaderej, AxoGen’s Chairman, Chief Executive Officer and President; and Pete Mariani, Executive Vice President and Chief Financial Officer. Karen will discuss the quarter and our outlook for the year, and Pete will provide an analysis of our financial performance and guidance, followed by a question-and-answer session.
Today’s call is being broadcast live via webcast, which is available on the Investors section of the AxoGen’s website. Following the end of the live call, a replay will be available -- in the Investors section of the company’s website at www.axogeninc.com.
Before we get started, I’d like to remind you that during this conference call, the company will make projections and forward-looking statements including our 2023 financial outlook and longer-term revenue and growth expectations, timing of our BLA submission, anticipated growth for revenue categories, penetration of core accounts, marketing opportunities with nerve applications associated with emergent trauma, breast, OMF and the surgical treatment of pain and new products, timing for the start of processing at our APC facility, launch of our HA+ Protector, optimism associated with key strategic pillars and our balance sheet.
Forward-looking statements are based on current beliefs and assumptions, and are not guarantees of future performance and are subject to risks and uncertainties, including, without limitation, the risks and uncertainties reflected in the company’s annual and periodic reports such as hospital staffing issues, regulatory process and approvals, APC renovation, timing and expense, surgeon and product adoption, and market awareness of our products.
Forward-looking statements are representative only as of the date they were made, and except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements. In addition, for a reconciliation of the non-GAAP measures -- including adjusted core and active account numbers, excluding the impact of Avive purchases, please reference today’s press release and our corporate presentation on the Investors section of the company’s website.